🇺🇸

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

·daily

US Corporate Distress Financial Stress SEC Filings — April 06, 2026

Across 40 filings in the USA Corporate Distress & Bankruptcy stream, outright distress is limited to one Chapter 11 bankruptcy (Charles & Colvard) and signals like DIP financing, forbearance agreements, covenant loosening, and reverse splits in 5 others, but the majority (28/40) involve new/expanded credit facilities, amendments, or notes issuances indicating proactive liquidity management amid potential pressures. No broad YoY/QoQ revenue declines reported, but isolated metrics show growth in acquired assets (e.g., VYKAT XR $190M 2025 revenue, INGREZZA $2.51B 2025) contrasting distress cases; sentiment skews positive/neutral (32/40) due to M&A premiums and financing access. Key themes include biotech M&A (NBIX-SLNO at 34-51% premiums, Profusa LOI), rail/RE securitizations, and covenant relief (e.g., Martin Midstream ICR to 1.65x, leverage to 5.5x). Portfolio-level pattern: 15/40 filings feature credit expansions/amendments (avg commitment +20-50%), signaling sector-wide deleveraging efforts; dilution risks in 4 cases (e.g., Greenpro shares doubled). Implications: Avoid deep distress names, favor M&A targets and strong refinancers; watch May-June catalysts for deal closes amid bankruptcy milestones.

40 high priority40 total filings
·daily

US Executive Officer Management Changes SEC — April 06, 2026

Across 31 filings on USA executive and director changes from April 6, 2026, the dominant theme is robust C-suite and board refreshment, with 18 new appointments/promotions (9 CFOs, 4 CEOs, 5+ directors) signaling strategic hiring for growth amid AI, energy demand, and profitability inflection points, versus 13 departures/retirements/terminations. Positive sentiment prevails in 35% of cases (11/31), particularly tech/health/energy sectors with hires boasting cap markets, ops, and scaling expertise (e.g., Oracle 20%+ organic revenue growth, Nerdy FY2026 rev guidance $180-190M, EBITDA breakeven). Neutral sentiment in 55% reflects orderly transitions without disagreements, but mixed signals like FuelCell director opposition (3.6M votes against) and sudden terminations (HealthEquity CTO) flag potential governance risks. No broad YoY revenue declines noted, but portfolio-level trend shows margin improvements in 4 cases (Nerdy +1000bps EBITDA margin implied), continuity in large caps (Cheniere seamless Chairman shift), and heightened retention incentives (Heron exec severance enhancements). Market implications include near-term catalysts from retirements (TVA CEO July 1) and M&A closes (Hologic go-private April 7), favoring longs in growth refreshes while monitoring small-cap churn (e.g., Treasure Global, Solo Brands OTC suspension). Overall, bullish for sectors with proven succession (energy/tech) vs. watch utilities/small caps.

31 high priority31 total filings
·daily

US Corporate Board Director Changes SEC Filings — April 06, 2026

Across 31 SEC filings on USA Board Room Changes from April 6, 2026, there is elevated C-suite and board turnover with 18 appointments/promotions (e.g., 9 CFO roles) and 13 departures/retirements, skewed positive in tech, energy, and insurance sectors amid growth narratives. Key period trends include strong historical performance like Hologic's 65% revenue growth and 241% share price rise under retiring CEO, Oracle's >20% YoY organic revenue growth, and Nerdy's FY2026 guidance of $180-190M revenue with breakeven EBITDA (1,000bps margin expansion from 2025). Neutral sentiment dominates (19/31), but positive tones in 9 filings highlight expertise additions for scaling (e.g., AI-driven firms like DeFi Development Corp.). Critical implications: CFO influx signals financial discipline for expansion in energy (Expand Energy, Murphy USA) and tech (Oracle, Nerdy); CEO retirements at TVA (July 1) and Hologic (April 7 post-LBO) pose succession risks. Portfolio pattern: 7/12 energy/utility filings show leadership continuity for LNG/AI demand, contrasting sporadic director oppositions (e.g., FuelCell's 3.6M votes against). No broad margin compression but isolated incentives (Broadwind STIP payouts) amid capex reinvestment.

31 high priority31 total filings
·daily

US Merger & Acquisition SEC Filings — April 06, 2026

The 11 filings reveal a surge in SPAC M&A pipeline activity, with two fresh IPOs (Inflection Point VI at $253M and QDRO at $200M, totaling $453M in new trusts) alongside extensions, updates, and delays in de-SPAC processes, signaling robust blank-check hunting amid favorable redemption dynamics. Completed takeovers dominate high-materiality events: Howmet's $1.8B aerospace acquisition, ProCap's AI-finance bolt-on adding $30B assets and thousands of users, Vireo's cannabis expansion to 10 states with 160+ dispensaries and 12M deliveries, and SWK's merger into RWAY involving $173.5M cash + 6.33M shares issued. Positive sentiment prevails in 4/11 filings (IPAC VI, Horizon, ProCap, Howmet, Vireo), contrasting neutral/mixed tones in SPAC delays and a low-materiality resignation. No explicit YoY/QoQ financial trends disclosed across filings, but capital deployed into trusts/deals highlights liquidity for M&A; SWK delisting and trust amendments indicate maturing SPAC lifecycle risks. Portfolio implication: Elevated US M&A momentum in SPACs, aerospace, fintech, and cannabis, with arbitrage ops in redemption premiums and de-SPAC catalysts through Q2 2026.

11 high priority11 total filings
·monthly

US Pre-Market SEC Filings Roundup — April 06, 2026

Overnight SEC filings reveal a proxy-heavy stream dominated by DEF 14A/DEFA14A for upcoming May 2026 AGMs across financials (JPM, SCHW, GNW), REITs (MAA), and others, signaling routine governance but with positive comp tweaks (CNP exculpation). Biotech M&A surges with Neurocrine-Soleno $2.9B deal (51% premium, VYKAT XR $190M 2025 rev) and Profusa-Bio Insights $30M LOI, alongside strategic reviews (Playtika) and mergers (Clear Channel). Period trends mixed: Airsculpt rev -15.8% YoY to $151.8M (cases -15.6%), JPM record $185.6B rev/20% ROTCE, Laird Superfood acquiree +24% sales; aggregate 4/10 filings show rev declines avg -15%, offset by loss narrowing (Strategic Acquisitions net loss -67% YoY). Financing active with shelves (PodcastOne $150M, Ooma), SPAC IPOs (Inflection Point $253M), notes (Atlas $300M), but risks from going concerns (PodcastOne) and impairments (Airsculpt $4.6M). Capital allocation favors M&A/debt repayment over buybacks/dividends; insider activity limited but equity grants (Oxbridge NEOs). Key implications: Biotech/health catalysts near-term, monitor aesthetics weakness and SPAC dilutions.

21 high priority23 medium44 total filings
·daily

S&P 500 Technology Sector SEC Filings — April 03, 2026

Across the 7 filings in the S&P 500 Technology stream (though skewed toward small-cap biotech, financials, and niche players), dominant themes include proxy statements for upcoming annual meetings (Aditxt, Camden), leadership compensation updates (Radian), auditor changes (Arcadia), shelf registrations for resale (Lyell), institutional portfolios (Adirondack), and stark financial deterioration (Token). Period-over-period trends reveal acute weakness in Token Communities with revenues plunging 85% YoY to $356k, gross margins collapsing 98% to $18k, and net loss of $464k vs prior profit, contrasting neutral stability elsewhere; no broad tech margin compression or growth patterns emerge due to diverse/non-core filers. Critical developments include Arcadia's auditor dismissal amid going concern warnings and material control weaknesses, signaling distress in ag-biosciences, while Aditxt's reverse split authorization flags liquidity risks. Portfolio-level patterns show proxy season catalysts in May 2026, limited insider conviction (none reported), and Adirondack's heavy tech exposure (Apple, Amazon). Market implications: Low conviction for tech longs, heightened risks in small caps, monitor governance votes for alpha.

3 high priority4 medium7 total filings
·daily

Nasdaq 100 Stocks SEC Filings — April 03, 2026

Proxy season is accelerating across NASDAQ-100 related filings with four companies (Mondelez, Aditxt, Camden National, Radian implied via comp) scheduling virtual annual meetings in May 2026, focusing on director elections, say-on-pay, auditor ratifications, and reverse splits. Period-over-period trends reveal stark contrasts: Token Communities suffered an 85% YoY revenue plunge to $356k, 87% drop in home sales, and gross margins shriveled 98% to $18k, while Mondelez reported solid 2025 net revenue growth and strong FCF amid cocoa volatility. Exec transitions signal caution—Intel's EVP/Chief Legal Officer exit effective June 1, 2026 (negative), contrasted by Radian's new Interim CFO compensation package ($500k base, $1M LTIP). Arcadia Biosciences' auditor switch highlights ongoing distress with going concern warnings and material control weaknesses from Dec 31, 2025 10-K. Lyell's S-3 enables resale of 1.95M shares from $25.61 milestone pricing (premium to $13.32 initial), potentially pressuring supply. Overall themes: resilient consumer staples (MDLZ) vs. biotech/small-cap distress (ADTX, LYEL, RKDA, TKCM), with limited capital allocation or insider trading signals but high event density for catalysts.

5 high priority5 medium10 total filings
·daily

S&P 500 Financials Sector SEC Filings — April 03, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (though including diverse sectors), overarching themes include a heavy proxy season with 15+ annual/special meetings clustered in May 2026 (e.g., Valley National Bancorp May 18, Certara May 14), signaling routine governance but potential shareholder activism risks. Period-over-period trends reveal polarized performance: 6/12 companies with financial metrics showed YoY revenue growth averaging +22% (EACO +17.7%, Karman +36.6%), but margins mixed with compressions (Karman -290bps operating) and income declines (TCW Direct Lending -44% investment income); lending firms like TCW and Generation Income reported widening losses amid higher expenses. Forward-looking catalysts abound in April-May 2026: tender offer extensions (Lisata to Apr 13), spin-offs (First Tracks Apr 20), M&A approvals (Prosperity Bancshares-Stellar, European Wax going-private May 7), and Nasdaq hearings (Aeries, Twin Vee by Apr 9). Capital allocation highlights shareholder returns (GE Vernova doubled dividend to $2/share, +$3.6B buybacks/repurchases) contrasting debt stresses (Atlantic International defaults, United Homes covenant waivers). Insider activity sparse but neutral (no buys/sells flagged); sentiment mixed/neutral dominant (28/50 neutral), with financials like Valley National, Radian Group, FIS showing stable governance. Portfolio implications: overweight growth outliers like EACO/Karman, monitor delisting risks in small caps, and position for M&A catalysts in banks/insurers.

23 high priority27 medium50 total filings
·daily

S&P 500 Consumer Staples Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader context), proxy season dominates with 20+ DEF/DEFA14A filings signaling annual meetings in May 2026, highlighting mixed 2025 performance: solid adjusted metrics (e.g., Kraft Heinz adj EPS $2.60, Mondelez >$3B FCF target) amid GAAP challenges and cocoa volatility. Period-over-period trends show selective growth (McCormick strong vote approvals, Deluxe Data Solutions +31.3% YoY) but declines in others (Elventix cash -64.4%, Print -5.7%). Capital allocation leans positive with dividends declared (Alta Equipment $0.625/DS) and redemptions (Moog 2027 notes). CMBS trusts report uniform special servicer changes for Potomac Mills (8.9%-2.1% pool weights) and Essex loans to Torchlight/KeyBank, neutral but watch for loan distress. No widespread insider trading patterns; forward-looking includes Mondelez 3-5% organic growth long-term, Relmada Phase 3 mid-2026. Portfolio-level: 3/3 Staples firms (MDLZ, KHC, MKC) show resilient adj growth vs. sector headwinds, but mixed sentiment prevails. Actionable: Buy dips in staples on FCF strength; monitor CMBS for CRE risks spilling to staples supply chains.

24 high priority26 medium50 total filings
·daily

S&P 500 Industrials Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Industrials stream (with some cross-sector context), proxy season dominates with 20+ DEF/DEFA14A filings highlighting robust 2025 performance in key industrials like GE Vernova (revenue +9% YoY to $38B, backlog $150B) and ITT Inc. (revenue +8% YoY to $3.9B, FCF $555M), amid capital returns exceeding $4B combined via buybacks and doubled dividends; however, small-cap distress signals emerge with delisting notices (Twin Vee, Matinas). Period-over-period trends show 3/5 detailed industrials with double-digit revenue/earnings growth (avg +10% revenue, +50% EBITDA), but REITs like Generation Income Properties report widening net losses (-31% YoY) and equity deficits. M&A activity accelerates (ITT's $4.8B SPX FLOW deal closed Mar 2026, Aurinia acquiring Kezar Q2 2026), while forward-looking catalysts cluster in May 2026 annual meetings and Q1 earnings (e.g., SouthState Apr 23). No widespread insider selling patterns, but neutral transitions/resignations in 10+ filings signal steady governance; capital allocation tilts bullish with $10B+ buyback authorizations. Portfolio-level, 7/10 high-materiality filings bullish on orders/backlogs, positioning industrials for reacceleration despite mixed bank/health crossovers.

26 high priority24 medium50 total filings
·daily

S&P 500 Energy Sector SEC Filings — April 03, 2026

In a very quiet session for S&P 500 Energy with only one filing, Token Communities Ltd. (TKCM) 10-K dominates as the highest materiality event (9/10), revealing severe FY2025 operational distress with revenues crashing 85% YoY to $356,579 from $2.43M, home sales plunging 87% to $315k, gross margins contracting 98% to $18,499, and a net loss of $464k versus $1.28M profit prior year. Counterbalancing trends include total assets expanding 51% YoY to $6.04M, inventory surging 47% to $5.82M, cash jumping 142% to $62,841, and new construction in progress at $157k, signaling aggressive capacity buildup amid $157k investing cash outflow. Liabilities climbed 29% to $11.24M with a fresh $3.17M construction loan, widening the stockholders' deficit 10% to $5.20M from $4.74M, while shares outstanding held steady at 2.10B. Mixed sentiment stems from plummeting profitability versus asset/inventory expansion for potential rebound. No portfolio-level patterns emerge from the single filing, but TKCM's metrics highlight outlier distress in a sector context, with implications for turnaround potential if housing/energy-linked demand recovers, though leverage risks loom large.

1 high priority1 total filings
·daily

US Material Events SEC 8-K Filings — April 03, 2026

Across the 50 filings from April 3, 2026, key themes include elevated executive churn (18 resignations/appointments/transitions, mostly neutral), aggressive financing maneuvers (15+ loans/amendments/raises amid tight liquidity), and a surge in M&A/SPAC activity (8 deals, particularly in biotech/pharma and energy, with positive sentiment in 6/8). Limited explicit period-over-period financials show no broad revenue/margin declines, but where present (e.g., TransAct rent -7% initially), cost savings emerge; forward-looking catalysts cluster in Q2 2026 (merger closes, tenders). Distress signals in 4 firms (defaults, waivers) contrast with bullish capital raises ($10M+ Entera Bio, $3M Mobix) and advisory extensions (Braemar). Portfolio-level: Biotech leads M&A (Aurinia-Kezar $110M+ implied value), real estate financing clusters (NexPoint $6M loan), signaling opportunistic growth amid leadership flux. Actionable: Prioritize M&A targets for takeout premiums, monitor covenant waivers for merger risks.

50 high priority50 total filings
·daily

Dow Jones 30 Stocks SEC Filings — April 03, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (with broader coverage including related small/mid-caps and SPACs), overarching themes include intense proxy season preparations for May 2026 annual meetings (15+ filings like GEV, BAC, Valley, EVgo), robust blue-chip growth (GE Vernova +9% YoY revenue to $38B, +213% net income to $4.9B; Bank of America +13% NI to $30.5B, +7% revenue to $113.1B), and elevated SPAC/M&A activity (12+ deals/extensions like OSRH license, Crown Reserve SPAC, ENVIRI $3.04B sale). Period-over-period trends reveal strong revenue expansion averaging ~25% YoY in reporting firms (Karman +36.6% to $471.5M, GEV +9%, BofA +7%) but mixed margins (Karman -290bps to 15.5%, NeOnc Q4 net loss +422% to $62.1M) and cash flow swings (Karman op cash -$22M vs +$26M YoY). Capital allocation favors shareholders at blue-chips (GEV dividend doubled to $2/share, buyback auth +$4B to $10B; BofA 28% TSR), while small caps face delisting risks (Twin Vee, Matinas). Portfolio-level patterns signal industrial/defense strength (record GEV $150B backlog), banking resilience, but biotech/delisting vulnerabilities; actionable now: buy blue-chip dips, avoid listing-threatened names ahead of catalysts.

33 high priority17 medium50 total filings
·daily

US SEC Filings Daily Market Digest — April 03, 2026

The April 3, 2026, SEC filings reveal a dominant theme of proxy season kickoff with over 20 DEF 14A/DEFA14A filings scheduling May 2026 AGMs for director elections, say-on-pay, and auditor ratifications, signaling routine governance amid neutral sentiment. Strong performers include EACO (17.7% YoY Q2 sales growth to $117.8M, 44.9% net income surge), GE Vernova (9% YoY revenue to $38B, 213% net income to $4.9B), and LXP Industrial Trust (29.8% TSR, 97.1% occupancy +350bps YoY), highlighting industrial/defense resilience with robust backlogs and capital recycling. Mixed results prevail in REITs (Generation Income revenue -0.2% YoY, net loss widened to $6.4M) and small caps (BT Brands revenue -9% YoY but EBITDA +138%, Super League FY revenue -30% but cash to $14.4M). M&A/spin-off activity surges with Lisata tender extension to Apr 13, First Tracks spin-off distribution Apr 20, European Wax going-private vote May 7, and OSR's $815M milestone license deal targeting Apr 30 close. Portfolio-level trends show 5/12 reporting companies with >15% YoY revenue growth (avg +25%), but 4/12 with margin compression (avg -150bps); capital returns strong in GEV (dividend doubled to $2/share, buybacks +$4B auth). Risks cluster in debt covenants (Atlantic dispute, United Homes waivers) and delistings (Aeries), while opportunities lie in undervalued turnarounds and catalysts like May votes.

23 high priority27 medium50 total filings
·daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 03, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary intelligence stream (though spanning broader sectors via 13Fs and trusts), dominant themes include a surge in proxy statements (15+ filings) for annual/special meetings in May-June 2026 focused on director elections, compensation votes, and auditor ratifications, signaling peak governance season. Financial trends show robust revenue/volume growth in outliers like AsiaFIN Holdings (+51.5% YoY revenue), Figure Technology (+102% YoY loan volume), and Bank of America (+13% YoY net income), but persistent margin compression (e.g., AsiaFIN -490bps gross margin) and covenant breaches (Flux Power EBITDA default). Key developments: First Tracks Biotherapeutics spin-off (Apr 20 distribution), Forian Inc. take-private at 22.6% premium (Q2 2026 close), multiple CMBS servicer switches to Torchlight, and financing expansions (e.g., Blue Owl $100M revolver). No major insider trading patterns noted (zero buys/sells detailed), limited capital allocation shifts (e.g., AFG $707M returns), and neutral sentiment overall (70% filings). Portfolio implications: Watch Consumer Discretionary proxies (YUM, Braemar) for stability amid sector volatility; alpha from spin-offs and M&A catalysts.

29 high priority21 medium50 total filings
·daily

S&P 500 Healthcare Sector SEC Filings — April 03, 2026

Across 28 filings in the USA S&P 500 Healthcare stream (with broader financial context), proxy season dominates with 8+ AGMs scheduled for May 2026, highlighting governance focus amid executive transitions in biotechs (resignations, deaths, appointments). Biotech firms show cost-control measures like lease terminations (Kezar paid $1.3M fee), option repricings (Skye for 2.4M shares at $0.615), and auditor switches (Arcadia amid going concern issues), signaling cash preservation in a challenging environment. AbbVie slashed 2026 adj EPS guidance by $0.41 to $13.96-$14.16 due to $744M Q1 IPR&D expense, a major bearish signal for pharma; contrast with CVS Health's robust 2025 revenue of $402.1B and $10.6B op cash flow. Small biotechs like Elventix report deepening losses ($31k Q1, cash -64% to $890) and equity deficits, while HeartSciences faces leadership void post-COO death but reaffirms no operational disruption. No widespread insider buying/selling, limited capital returns data (American Financial returned $707M), and mortgage trusts show servicer changes without financial impacts. Portfolio trend: Neutral-to-mixed sentiment (12/28 neutral), with healthcare outliers in negative guidance/leadership risks vs positive large-cap performance; watch May catalysts for voting outcomes and earnings.

12 high priority16 medium28 total filings
·daily

US Executive Compensation Proxy SEC Filings — April 03, 2026

Across 50 DEF 14A filings for 2026 proxy statements, a dominant theme is robust 2025 financial performance in industrials, REITs, and tech sectors, with 12 companies reporting revenue growth exceeding 10% YoY (e.g., GE Vernova +9%, CBRE +13.4%, ITT +8%) and strong capital returns via dividends and buybacks totaling billions (e.g., GE Vernova $3.6B returned, Royal Gold $1.2B since 2000). Margin expansions and FFO/NOI growth highlight operational resilience (e.g., LXP occupancy +350bps to 97.1%, Skyworks non-GAAP margin 24.4%), though food and select REITs show mixed results with GAAP declines amid volatility (e.g., NHI net income -3.5% YoY, Kraft Heinz GAAP EPS -$4.93). M&A activity surges as a catalyst (9 deals noted, including GE Vernova's $5.3B Prolec, ITT's $4.775B SPX FLOW), signaling consolidation and growth conviction. Capital allocation favors shareholders with dividend hikes (e.g., GE Vernova doubled to $2/share, Skyworks to $0.71) and buybacks, while forward-looking guidance points to sustained growth (e.g., Mondelez 3-5% organic revenue). Portfolio-level trends indicate outperformance vs. benchmarks (e.g., CBRE TSR beats S&P 500 across 1/3/5yr), but watch for say-on-pay votes and board refreshes at May-June 2026 meetings. Overall, bullish for industrials/REITs, neutral-mixed elsewhere, with alpha in M&A plays.

50 high priority50 total filings
·daily

US IPO Pipeline SEC S-1 Filings — April 03, 2026

The IPO Pipeline stream reveals a surge in activity with three new S-1 IPO filings (Auddia, VIDA Global, American Rebel) and two S-4 merger registrations (Prosperity Bancshares, Live Oak Acquisition Corp. V), highlighting a diverse mix of audio tech, AI, consumer holdings, banking, and SPAC de-SPAC plays amid a 2026 IPO resurgence. Overarching themes include pervasive execution risks like going concern opinions, Nasdaq compliance histories via reverse splits, founder voting controls exceeding 85%, and high redemption/dilution potentials, tempered by strategic M&A pursuits and committed financings such as $126.5M PIPE. Period trends show cash burn pressures (e.g., Auddia's $3.2M cash at Dec 31, 2025 despite $7.1M 2025 raise and $0.9M YTD to Mar 2026) contrasting with acquisition expansions (American Rebel's $20+MM in minority stakes). Mixed sentiments dominate (4/5 filings), with VIDA's positive outlook as the outlier in hot AI sector. Market implications point to volatile near-term pops for IPOs but elevated failure risks, regulatory bottlenecks as key catalysts, and opportunities in merger arb for fixed-ratio deals.

5 high priority5 total filings
·daily

Global High-Priority Regulatory Events — April 03, 2026

Across 50 filings on April 3, 2026, dominant themes include financial distress in Indian companies (defaults totaling ₹366+ Cr across Dharani Sugars, Interworld Digital, Madhucon Projects; insolvencies at JCT Ltd and Baron Infotech) contrasting with robust US performance in defense/industrials (Karman Holdings revenue +36.6% YoY to $471.5M, backlog + to $801M; GE Vernova revenue +9% YoY to $38B, net income +213% to $4.9B). Margin pressures evident in Karman (-2.9 pts to 15.5%) and TCW Direct Lending (income -44% YoY), while capital allocation shines with GE Vernova's doubled dividend to $2/share and $10B buyback authorization. Neutral routine disclosures dominate Indian regulatory actions (no encumbrances in 7+ firms like Samkrg Pistons, Nutech Global), signaling promoter stability. Forward catalysts cluster in May 2026 annual meetings (Stereotaxis, Certara, NCR Atleos, GE Vernova) and April 7 RBI auction. Portfolio implications: Avoid Indian distress names, favor US growth outliers amid global high-priority events like M&A (Auddia exploring), mergers (United Homes pending May 31), and BTC trust launch.

50 high priority50 total filings
·daily

US Earnings Financial Results SEC Filings — April 03, 2026

Across 12 US SEC filings in the Financial Results & Earnings stream, results reveal a bifurcated landscape with robust revenue growth in defense (Karman +36.6% YoY) and professional services (RCM +14.7% YoY, Concentrix +5.4% YoY, Ooma +7% YoY) offsetting sharp declines in lending/BDCs (TCW Direct -44% YoY, TCW VII -35.1% YoY), microcaps (Totaligent -99.5% YoY, Token -85% YoY), and others (POWERDYNE -7.2% YoY). Margin trends are mixed, with compression in 7/12 companies (e.g., Karman -2.9 pts, Concentrix operating -30% YoY) but improvements in adjusted EBITDA for Karman (+37%), Ooma (+46%), and RCM (+19%). Net losses narrowed in loss-making firms like GOOD GAMING (-75.5%), but cash burn persists in 8/12, with liabilities rising in 6/12 amid dilution and debt increases. Capital allocation shows shareholder focus via buybacks (RCM 114k shares, Concentrix 1k shares) and dividends (Concentrix $23M), signaling conviction in outperformers. Portfolio-level pattern: small-cap deterioration (8/12 revenue down avg -50% YoY) vs mid-cap resilience, implying rotation opportunities from distressed names to growth segments like defense/services. No insider activity or explicit guidance noted, but improving debt ratios (Karman 1.52 from 2.25) and backlog growth flag early recovery signals.

12 high priority12 total filings
← All geographies